These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17951168)

  • 1. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
    Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
    Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
    Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble Fas ligand in patients with gastric carcinoma.
    Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
    Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
    Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
    Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
    Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
    Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
    Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
    Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
    Yuan BJ; Liu ZZ; Ding XR; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
    Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
    Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction.
    Briana DD; Baka S; Boutsikou M; Liosi S; Vraila VM; Gourgiotis D; Hassiakos D; Malamitsi-Puchner A
    Neonatology; 2010; 97(1):31-5. PubMed ID: 19590243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of FasL mRNA, sFasL and their regulatory effect on T lymphocyte subsets in patients with severe acute pancreatitis].
    Qin Y; Liao P; He S; Yin Y; Song S; Hu J; Zheng P
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Nov; 29(11):1189-92. PubMed ID: 24200068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.
    Hoffmann TK; Dworacki G; Tsukihiro T; Meidenbauer N; Gooding W; Johnson JT; Whiteside TL
    Clin Cancer Res; 2002 Aug; 8(8):2553-62. PubMed ID: 12171883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
    Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
    Jiao XL; Chen D; Wang JG; Zhang KJ
    Eur Rev Med Pharmacol Sci; 2014; 18(4):509-15. PubMed ID: 24610617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
    Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
    Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
    Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
    Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.